ALAS2 and autosomal erythropoietic protoporphyria: Overall, our findings in a fixed genetic background group could support the hypothesis that the overexpression of ALAS2 mRNA in EPP patients likely contributes to the disease etiology and therefore is a potential target for developing new treatment options in EPP (Ducamp et al., 2021; Halloy et al., 2021).